Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.76 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.62 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.61 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6188789 | 0.89 | EGFR (0.80) | EGFRERBB2AURKAERBB4HDAC3 | |
| SCHEMBL6188401 | 0.87 | EGFR (0.67) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL2991833 | 0.83 | EGFR (1.00) | EGFRERBB2AURKAGRM1ERBB4 | |
| SCHEMBL29923578 | 0.83 | EGFR (1.00) | EGFRERBB2AURKAGRM1ERBB4 | |
| SCHEMBL31299934 | 0.83 | EGFR (1.00) | EGFRERBB2AURKAGRM1ERBB4 | |
| SCHEMBL641359 | 0.82 | EGFR (0.75) | EGFRERBB2AURKAGRM1 | |
| Hydrochloric Acid SCHEMBL7764930 | 0.82 | EGFR (0.97) | EGFRERBB2AURKAGRM1ERBB4 | |
| SCHEMBL6188729 | 0.81 | EGFR (0.77) | EGFRERBB2AURKAGRM1 | |
| SCHEMBL2248477 | 0.81 | EGFR (0.77) | EGFRERBB2ERBB4HDAC3HDAC4 | |
| SCHEMBL27686240 | 0.80 | EGFR (0.63) | EGFRERBB2AURKARPS6KB1GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | claimed |
| CN-1370535-A | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | claimed |
| CN-1194692-C | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2005-03-30 | — | — | CN | disclosed |
| CN-1370535-A | Method of inhibiting skin damage of vitamin A analog | WANER LONGBER CO (US) | 2002-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885AURKA 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.